Critical care of the end-stage liver disease patient awaiting liver transplantation

Liver Transplantation

Volumn 17, Issue 5, 2011, Pages 496-510

  Findlay, James Y ^a   Fix, Oren K ^b   Paugam Burtz, Catherine ^d   Liu, Linda ^c   Sood, Puneet ^b   Tomlanovich, Stephen J ^b   Emond, Jean ^e  

^a MAYO CLINIC   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c UNIVERSITY OF CALIFORNIA   (United States)

^d BEAUJON HOSPITAL   (France)

^e Och Spine at New York Presbyterian Hospitals   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACUTE KIDNEY FAILURE; ARTIFICIAL VENTILATION; BACTERIAL COLONIZATION; BRAIN FUNCTION; DIFFERENTIAL DIAGNOSIS; END STAGE LIVER DISEASE; HEART FAILURE; HEART HEMODYNAMICS; HEPATIC ENCEPHALOPATHY; HEPATOPULMONARY SYNDROME; HEPATORENAL SYNDROME; HUMAN; INFECTION; INTENSIVE CARE; INTENSIVE CARE UNIT; KIDNEY TRANSPLANTATION; LIVER TRANSPLANTATION; LUNG INSUFFICIENCY; MULTIDRUG RESISTANCE; PATHOGENESIS; PATIENT CARE; PORTOPULMONARY HYPERTENSION; PRIORITY JOURNAL; RENAL REPLACEMENT THERAPY; REVIEW; SCREENING TEST; SEPSIS; TREATMENT CONTRAINDICATION;

ACUTE KIDNEY INJURY; CARDIOVASCULAR DISEASES; CRITICAL CARE; CRITICAL ILLNESS; END STAGE LIVER DISEASE; FIBROSIS; HEPATIC ENCEPHALOPATHY; HUMANS; INTENSIVE CARE UNITS; LIVER TRANSPLANTATION; RENAL REPLACEMENT THERAPY; SEPSIS; TREATMENT OUTCOME;

EID: 79955053791     PISSN: 15276465     EISSN: 15276473     Source Type: Journal    
DOI: 10.1002/lt.22269     Document Type: Review

References (131)

1. Cholongitas E, Senzolo M, Patch D, Kwong K, Nikolopoulou V, Leandro G, et al. Risk factors, sequential organ failure assessment and model for end-stage liver disease scores for predicting short term mortality in cirrhotic patients admitted to intensive care unit. Aliment Pharmacol Ther 2006; 23: 883-893.
2. Das V, Boelle PY, Galbois A, Guidet B, Maury E, Carbonell N, et al. Cirrhotic patients in the medical intensive care unit: early prognosis and long-term survival. Crit Care Med 2010; 38: 2108-2116.
3. Robert R, Veinstein A,. Prognosis in patients with cirrhosis in intensive care [in French]. Gastroenterol Clin Biol 2003; 27: 877-881. (Pubitemid 37362753)
4. Ferenci P, Lockwood A, Mullen K, Tarter R, Weissenborn K, Blei AT,. Hepatic encephalopathy-definition, nomenclature, diagnosis, and quantification: final report of the working party at the 11th World Congresses of Gastroenterology, Vienna, 1998. Hepatology 2002; 35: 716-721. (Pubitemid 34183979)
5. Polson J, Lee WM,. AASLD position paper: the management of acute liver failure. Hepatology 2005; 41: 1179-1197. (Pubitemid 40593928)
6. Sen S, Williams R, Jalan R,. The pathophysiological basis of acute-on-chronic liver failure. Liver 2002; 22 (suppl 2): 5-13.
7. Bustamante J, Rimola A, Ventura PJ, Navasa M, Cirera I, Reggiardo V, Rodes J,. Prognostic significance of hepatic encephalopathy in patients with cirrhosis. J Hepatol 1999; 30: 890-895. (Pubitemid 29248991)
8. Blei AT, Cõrdoba J,; Practice Parameters Committee of the American College of Gastroenterology. Hepatic encephalopathy. Am J Gastroenterol 2001; 96: 1968-1976.
9. Ong JP, Aggarwal A, Krieger D, Easley KA, Karafa MT, Van Lente F, Arroliga AC, Mullen KD,. Correlation between ammonia levels and the severity of hepatic encephalopathy. Am J Med 2003; 114: 188-193. (Pubitemid 36294003)
10. Riordan SM, Williams R,. Treatment of hepatic encephalopathy. N Engl J Med 1997; 337: 473-479. (Pubitemid 27333050)
11. Shawcross DL, Davies NA, Williams R, Jalan R,. Systemic inflammatory response exacerbates the neuropsychological effects of induced hyperammonemia in cirrhosis. J Hepatol 2004; 40: 247-254. (Pubitemid 38115829)
12. Iacobone E, Bailly-Salin J, Polito A, Friedman D, Stevens RD, Sharshar T,. Sepsis-associated encephalopathy and its differential diagnosis. Crit Care Med 2009; 37: S331-S336.
13. Norenberg MD, Rao KV, Jayakumar AR,. Mechanisms of ammonia-induced astrocyte swelling. Metab Brain Dis 2005; 20: 303-318. (Pubitemid 43029804)
14. Donovan JP, Schafer DF, Shaw BW Jr, Sorrell MF,. Cerebral oedema and increased intracranial pressure in chronic liver disease. Lancet 1998; 351: 719-721. (Pubitemid 28105342)
15. Haussinger D, Kircheis G, Fischer R, Schliess F, vom Dahl S,. Hepatic encephalopathy in chronic liver disease: a clinical manifestation of astrocyte swelling and low-grade cerebral edema? J Hepatol 2000; 32: 1035-1038. (Pubitemid 30368099)
16. Shawcross DL, Shabbir SS, Taylor NJ, Hughes RD,. Ammonia and the neutrophil in the pathogenesis of hepatic encephalopathy in cirrhosis. Hepatology 2010; 51: 1062-1069.
17. Vaquero J, Polson J, Chung C, Helenowski I, Schiodt FV, Reisch J, et al. Infection and the progression of hepatic encephalopathy in acute liver failure. Gastroenterology 2003; 125: 755-764. (Pubitemid 37070693)
18. Guevara M, Bru C, Gines P, Fernandez-Esparrach G, Sort P, Bataller R, et al. Increased cerebrovascular resistance in cirrhotic patients with ascites. Hepatology 1998; 28: 39-44. (Pubitemid 28299983)
19. Bass NM, Mullen KD, Sanyal A, Poordad F, Neff G, Leevy CB, et al. Rifaximin treatment in hepatic encephalopathy. N Engl J Med 2010; 362: 1071-1081.
20. Curioso WH, Monkemuller KE,. Neomycin should not be used to treat hepatic encephalopathy. BMJ 2001; 323: 233. (Pubitemid 32682106)
21. Reding P, Duchateau J, Bataille C,. Oral zinc supplementation improves hepatic encephalopathy. Results of a randomised controlled trial. Lancet 1984; 2: 493-495. (Pubitemid 14069766)
22. Cõrdoba J, Lõpez-Hellín J, Planas M, Sabín P, Sanpedro F, Castro F, et al. Normal protein diet for episodic hepatic encephalopathy: results of a randomized study. J Hepatol 2004; 41: 38-43. (Pubitemid 39005150)
23. Kircheis G, Nilius R, Held C, Berndt H, Buchner M, Gortelmeyer R, et al. Therapeutic efficacy of L-ornithine-L-aspartate infusions in patients with cirrhosis and hepatic encephalopathy: results of a placebo-controlled, double-blind study. Hepatology 1997; 25: 1351-1360. (Pubitemid 27250753)
24. Jalan R, Wright G, Davies NA, Hodges SJ,. L-Ornithine phenylacetate (OP): a novel treatment for hyperammonemia and hepatic encephalopathy. Med Hypotheses 2007; 69: 1064-1069. (Pubitemid 47430227)
25. Davies NA, Wright G, Ytrebo LM, Stadlbauer V, Fuskevag OM, Zwingmann C, et al. L-ornithine and phenylacetate synergistically produce sustained reduction in ammonia and brain water in cirrhotic rats. Hepatology 2009; 50: 155-164.
26. Als-Nielsen B, Gluud LL, Gluud C,. Benzodiazepine receptor antagonists for hepatic encephalopathy. Cochrane Database Syst Rev 2004; CD002798.
27. Hassanein TI, Tofteng F, Brown RS Jr, McGuire B, Lynch P, Mehta R, et al. Randomized controlled study of extracorporeal albumin dialysis for hepatic encephalopathy in advanced cirrhosis. Hepatology 2007; 46: 1853-1862.
28. Khuroo MS, Farahat KL,. Molecular adsorbent recirculating system for acute and acute-on-chronic liver failure: a meta-analysis. Liver Transpl 2004; 10: 1099-1106. (Pubitemid 39248406)
29. Madoff DC, Wallace MJ, Ahrar K, Saxon RR,. TIPS-related hepatic encephalopathy: management options with novel endovascular techniques. Radiographics 2004; 24: 21-36. (Pubitemid 38134589)
30. Fasolato S, Angeli P, Dallagnese L, Maresio G, Zola E, Mazza E, et al. Renal failure and bacterial infections in patients with cirrhosis: epidemiology and clinical features. Hepatology 2007; 45: 223-229. (Pubitemid 46144382)
31. Foreman MG, Mannino DM, Moss M,. Cirrhosis as a risk factor for sepsis and death: analysis of the National Hospital Discharge Survey. Chest 2003; 124: 1016-1020. (Pubitemid 37123324)
32. Borzio M, Salerno F, Piantoni L, Cazzaniga M, Angeli P, Bissoli F, et al. Bacterial infection in patients with advanced cirrhosis: a multicentre prospective study. Dig Liver Dis 2001; 33: 41-48. (Pubitemid 32186174)
33. Gustot T, Durand F, Lebrec D, Vincent JL, Moreau R,. Severe sepsis in cirrhosis. Hepatology 2009; 50: 2022-2033.
34. Byl B, Roucloux I, Crusiaux A, Dupont E, Deviere J,. Tumor necrosis factor alpha and interleukin 6 plasma levels in infected cirrhotic patients. Gastroenterology 1993; 104: 1492-1497. (Pubitemid 23235425)
35. Le Moine O, Marchant A, De Groote D, Azar C, Goldman M, Deviere J,. Role of defective monocyte interleukin-10 release in tumor necrosis factor-alpha overproduction in alcoholics cirrhosis. Hepatology 1995; 22: 1436-1439.
36. Arvaniti V, D'Amico G, Fede G, Manousou P, Tsochatzis E, Pleguezuelo M, Burroughs AK,. Infections in patients with cirrhosis increase mortality 4-fold and should be used in determining prognosis. Gastroenterology 2010; 139: 1246-1256.
37. Cholongitas E, Betrosian A, Senzolo M, Shaw S, Patch D, Manousou P, et al. Prognostic models in cirrhotics admitted to intensive care units better predict outcome when assessed at 48 h after admission. J Gastroenterol Hepatol 2008; 23: 1223-1227.
38. Katoonizadeh A, Laleman W, Verslype C, Wilmer A, Maleux G, Roskams T, Nevens F,. Early features of acute-on-chronic alcoholic liver failure: a prospective cohort study. Gut 2010; 59: 1561-1569.
39. Dellinger RP, Levy MM, Carlet JM, Bion J, Parker MM, Jaeschke R, et al. Surviving Sepsis Campaign: international guidelines for management of severe sepsis and septic shock: 2008. Crit Care Med 2008; 36: 296-327.
40. Sun HY, Cacciarelli TV, Singh N,. Impact of pretransplant infections on clinical outcomes of liver transplant recipients. Liver Transpl 2010; 16: 222-228.
41. Russell DL, Flood A, Zaroda TE, Acosta C, Riley MM, Busuttil RW, Pegues DA,. Outcomes of colonization with MRSA and VRE among liver transplant candidates and recipients. Am J Transplant 2008; 8: 1737-1743.
42. Bert F, Bellier C, Lassel L, Lefranc V, Durand F, Belghiti J, et al. Risk factors for Staphylococcus aureus infection in liver transplant recipients. Liver Transpl 2005; 11: 1093-1099. (Pubitemid 41341759)
43. Paterson DL, Rihs JD, Squier C, Gayowski T, Sagnimeni A, Singh N,. Lack of efficacy of mupirocin in the prevention of infections with Staphylococcus aureus in liver transplant recipients and candidates. Transplantation 2003; 75: 194-198. (Pubitemid 36139671)
44. Bode LG, Kluytmans JA, Wertheim HF, Bogaers D, Vandenbroucke-Grauls CM, Roosendaal R, et al. Preventing surgical-site infections in nasal carriers of Staphylococcus aureus. N Engl J Med 2010; 362: 9-17.
45. Hagen EA, Lautenbach E, Olthoff K, Blumberg EA,. Low prevalence of colonization with vancomycin-resistant Enterococcus in patients awaiting liver transplantation. Am J Transplant 2003; 3: 902-905. (Pubitemid 36827914)
46. Bakir M, Bova JL, Newell KA, Millis JM, Buell JF, Arnow PM,. Epidemiology and clinical consequences of vancomycin-resistant enterococci in liver transplant patients. Transplantation 2001; 72: 1032-1037. (Pubitemid 32924073)
47. McNeil SA, Malani PN, Chenoweth CE, Fontana RJ, Magee JC, Punch JD, et al. Vancomycin-resistant enterococcal colonization and infection in liver transplant candidates and recipients: a prospective surveillance study. Clin Infect Dis 2006; 42: 195-203. (Pubitemid 43054190)
48. Paterson DL, Singh N, Rihs JD, Squier C, Rihs BL, Muder RR,. Control of an outbreak of infection due to extended-spectrum beta-lactamase-producing Escherichia coli in a liver transplantation unit. Clin Infect Dis 2001; 33: 126-128. (Pubitemid 32554514)
49. MÃller S, Bendtsen F, Henriksen JH,. Splanchnic and systemic hemodynamic derangement in decompensated cirrhosis. Can J Gastroenterol 2001; 15: 94-106. (Pubitemid 32229439)
50. MÃller S, Henriksen JH,. Cardiovascular dysfunction in cirrhosis. Pathophysiological evidence of a cirrhotic cardiomyopathy. Scand J Gastroenterol 2001; 36: 785-794. (Pubitemid 32656551)
51. Wong F,. Cirrhotic cardiomyopathy. Hepatol Int 2009; 3: 294-304.
52. Kalaitzakis E, Bjornsson E,. Coronary artery disease in liver cirrhosis: does the aetiology of liver disease matter? J Hepatol 2009; 51: 962-963.
53. Tiukinhoy-Laing SD, Rossi JS, Bayram M, De Luca L, Gafoor S, Blei A, et al. Cardiac hemodynamic and coronary angiographic characteristics of patients being evaluated for liver transplantation. Am J Cardiol 2006; 98: 178-181. (Pubitemid 43975507)
54. Moreau R, Hadengue A, Soupison T, Kirstetter P, Mamzer MF, Vanjak D, et al. Septic shock in patients with cirrhosis: hemodynamic and metabolic characteristics and intensive care unit outcome. Crit Care Med 1992; 20: 746-750.
55. Plessier A, Denninger MH, Consigny Y, Pessione F, Francoz C, Durand F, et al. Coagulation disorders in patients with cirrhosis and severe sepsis. Liver Int 2003; 23: 440-448. (Pubitemid 37540983)
56. Rivers E, Nguyen B, Havstad S, Ressler J, Muzzin A, Knoblich B, et al. Early goal-directed therapy in the treatment of severe sepsis and septic shock. N Engl J Med 2001; 345: 1368-1377.
57. Fernandez J, Monteagudo J, Bargallo X, Jimenez W, Bosch J, Arroyo V, Navasa M,. A randomized unblinded pilot study comparing albumin versus hydroxyethyl starch in spontaneous bacterial peritonitis. Hepatology 2005; 42: 627-634. (Pubitemid 41233655)
58. Sort P, Navasa M, Arroyo V, Aldeguer X, Planas R, Ruiz-del-Arbol L, et al. Effect of intravenous albumin on renal impairment and mortality in patients with cirrhosis and spontaneous bacterial peritonitis. N Engl J Med 1999; 341: 403-409. (Pubitemid 29362513)
59. Vincent JL, Biston P, Devriendt J, Brasseur A, De Backer D,. Dopamine versus norepinephrine: is one better? Minerva Anestesiol 2009; 75: 333-337.
60. Russell JA, Walley KR, Singer J, Gordon AC, Hebert PC, Cooper DJ, et al. Vasopressin versus norepinephrine infusion in patients with septic shock. N Engl J Med 2008; 358: 877-887. (Pubitemid 351397087)
61. Russell JA, Walley KR, Gordon AC, Cooper DJ, Hebert PC, Singer J, et al. Dieter Ayers for the Vasopressin and Septic Shock Trial Investigators. Interaction of vasopressin infusion, corticosteroid treatment, and mortality of septic shock. Crit Care Med 2009; 37: 811-818.
62. McCormick PA, Donnelly C,. Management of hepatorenal syndrome. Pharmacol Ther 2008; 119: 1-6.
63. Luckner G, Mayr VD, Jochberger S, Wenzel V, Ulmer H, Hasibeder WR, Dunser MW,. Comparison of two dose regimens of arginine vasopressin in advanced vasodilatory shock. Crit Care Med 2007; 35: 2280-2285. (Pubitemid 47476224)
64. Torgersen C, Dunser MW, Wenzel V, Jochberger S, Mayr V, Schmittinger CA, Lorenz I, Schmid S, Westphal M, Grander W, Luckner G,. Comparing two different arginine vasopressin doses in advanced vasodilatory shock: a randomized, controlled, open-label trial. Intensive Care Med 2010; 36: 57-65.
65. Sprung CL, Annane D, Keh D, Moreno R, Singer M, Freivogel K, et al.; CORTICUS Study Group. Hydrocortisone therapy for patients with septic shock. N Engl J Med 2008; 358: 111-124.
66. Fernandez J, Escorsell A, Zabalza M, Felipe V, Navasa M, Mas A, et al. Adrenal insufficiency in patients with cirrhosis and septic shock: effect of treatment with hydrocortisone on survival. Hepatology 2006; 44: 1288-1295. (Pubitemid 44748379)
67. Heemann U, Treichel U, Loock J, Philipp T, Gerken G, Malago M, et al. Albumin dialysis in cirrhosis with superimposed acute liver injury: a prospective, controlled study. Hepatology 2002; 36: 949-958.
68. Shellman RG, Fulkerson WJ, DeLong E, Piantadosi CA,. Prognosis of patients with cirrhosis and chronic liver disease admitted to the medical intensive care unit. Crit Care Med 1988; 16: 671-678.
69. Przybylowski T, Krenke R, Fangrat A, Nasilowski J, Grabczak EM, Styczynski G, et al. Gas exchange abnormalities in patients listed for liver transplantation. J Physiol Pharmacol 2006; 57 (suppl 4): 313-323. (Pubitemid 44638215)
70. Mohamed R, Freeman JW, Guest PJ, Davies MK, Neuberger JM,. Pulmonary gas exchange abnormalities in liver transplant candidates. Liver Transpl 2002; 8: 802-808. (Pubitemid 35012291)
71. Schiffer E, Majno P, Mentha G, Giostra E, Burri H, Klopfenstein CE, et al. Hepatopulmonary syndrome increases the postoperative mortality rate following liver transplantation: a prospective study in 90 patients. Am J Transplant 2006; 6: 1430-1437. (Pubitemid 44030326)
72. Rolla G, Brussino L, Colagrande P, Dutto L, Polizzi S, Scappaticci E, et al. Exhaled nitric oxide and oxygenation abnormalities in hepatic cirrhosis. Hepatology 1997; 26: 842-847. (Pubitemid 27413646)
73. Schenk P,. The hepatopulmonary syndrome. Published in: Pulmonary Manifestations of Systemic Diseases Edited by Verleden GM, Demedts MG, Westhovens R, and Thomeer M. European Respiratory Society Monograph 2006; 34: 112-128.
74. Creagh-Brown BC, Griffiths MJ, Evans TW,. Bench-to-bedside review: inhaled nitric oxide therapy in adults. Crit Care 2009; 13: 221.
75. The Acute Respiratory Distress Syndrome Network. Ventilation with lower tidal volumes as compared with traditional tidal volumes for acute lung injury and the acute respiratory distress syndrome. N Engl J Med 2000; 342: 1301-1308.
76. Petrucci N, Iacovelli W,. Lung protective ventilation strategy for the acute respiratory distress syndrome. Cochrane Database Syst Rev 2007; CD003844.
77. Rodriguez-Roisin R, Krowka MJ, Herve P, Fallon MB,. Pulmonary-hepatic vascular disorders (PHD). Eur Respir J 2004; 24: 861-880. (Pubitemid 39504442)
78. Funk GC, Doberer D, Kneidinger N, Lindner G, Holzinger U, Schneeweiss B,. Acid-base disturbances in critically ill patients with cirrhosis. Liver Int 2007; 27: 901-909. (Pubitemid 47261943)
79. Varpula T, Valta P, Niemi R, Takkunen O, Hynynen M, Pettila VV,. Airway pressure release ventilation as a primary ventilatory mode in acute respiratory distress syndrome. Acta Anaesthesiol Scand 2004; 48: 722-731. (Pubitemid 38843392)
80. Bollen CW, van Well GT, Sherry T, Beale RJ, Shah S, Findlay G, et al. High frequency oscillatory ventilation compared with conventional mechanical ventilation in adult respiratory distress syndrome: a randomized controlled trial [ISRCTN24242669]. Crit Care 2005; 9: R430-R439.
81. Adhikari NK, Burns KE, Friedrich JO, Granton JT, Cook DJ, Meade MO,. Effect of nitric oxide on oxygenation and mortality in acute lung injury: systematic review and meta-analysis. BMJ 2007; 334: 779.
82. Hodgson C, Keating JL, Holland AE, Davies AR, Smirneos L, Bradley SJ, Tuxen D,. Recruitment manoeuvres for adults with acute lung injury receiving mechanical ventilation. Cochrane Database Syst Rev 2009; CD006667.
83. Briel M, Meade M, Mercat A, Brower RG, Talmor D, Walter SD, Slutsky AS, et al. Higher vs lower positive end-expiratory pressure in patients with acute lung injury and acute respiratory distress syndrome: systematic review and meta-analysis. JAMA 2010; 303: 865-873.
84. Chanques G, Jaber S, Barbotte E, Violet S, Sebbane M, Perrigault PF, Mann C, et al. Impact of systematic evaluation of pain and agitation in an intensive care unit. Crit Care Med 2006; 34: 1691-1699. (Pubitemid 43810050)
85. Girard TD, Kress JP, Fuchs BD, Thomason JW, Schweickert WD, Pun BT, et al. Efficacy and safety of a paired sedation and ventilator weaning protocol for mechanically ventilated patients in intensive care (Awakening and Breathing Controlled trial): a randomised controlled trial. Lancet 2008; 371: 126-134.
86. Kress JP, Pohlman AS, O'Connor MF, Hall JB,. Daily interruption of sedative infusions in critically ill patients undergoing mechanical ventilation. N Engl J Med 2000; 342: 1471-1477. (Pubitemid 30318270)
87. Payen JF, Bosson JL, Chanques G, Mantz J, Labarere J,. Pain assessment is associated with decreased duration of mechanical ventilation in the intensive care unit: a post Hoc analysis of the DOLOREA study. Anesthesiology 2009; 111: 1308-1316.
88. Payen JF, Chanques G, Mantz J, Hercule C, Auriant I, Leguillou JL, Binhas M, et al. Current practices in sedation and analgesia for mechanically ventilated critically ill patients: a prospective multicenter patient-based study. Anesthesiology 2007; 106: 687-695. (Pubitemid 46555612)
89. Riker RR, Shehabi Y, Bokesch PM, Ceraso D, Wisemandle W, Koura F, et al.; SEDCOM (Safety and Efficacy of Dexmedetomidine Compared With Midazolam) Study Group. Dexmedetomidine vs midazolam for sedation of critically ill patients: a randomized trial. JAMA 2009; 301: 489-499.
90. Burns KE, Adhikari NK, Keenan SP, Meade M,. Use of non-invasive ventilation to wean critically ill adults off invasive ventilation: meta-analysis and systematic review. BMJ 2009; 338: b1574.
91. Narita M, Hatano E, Nagata H, Yanagida A, Asechi H, Takahashi K, et al. Prophylactic respiratory management after liver resection with bilevel positive airway pressure ventilation: Report of three cases. Surg Today 2009; 39: 172-174.
92. Nagai S, Fujimoto Y, Kamei H, Nakamura T, Kiuchi T,. Noninvasive positive pressure ventilation to prevent respiratory collapse after extubation: clinical case reports. Transplant Proc 2009; 41: 3919-3922.
93. Narayanan Menon KV, Nyberg SL, Harmsen WS, DeSouza NF, Rosen CB, Krom RA, Wiesner RH,. MELD and other factors associated with survival after liver transplantation. Am J Transplant 2004; 4: 819-825. (Pubitemid 38637583)
94. Cholongitas E, Senzolo M, Patch D, Shaw S, O'Beirne J, Burroughs AK,. Cirrhotics admitted to intensive care unit: the impact of acute renal failure on mortality. Eur J Gastroenterol Hepatol 2009; 21: 744-750.
95. Cruz DN, Bolgan I, Perazella MA, Bonello M, de Cal M, Corradi V, et al. North East Italian Prospective Hospital Renal Outcome Survey on Acute Kidney Injury (NEiPHROS-AKI): targeting the problem with the RIFLE Criteria. Clin J Am Soc Nephrol 2007; 2: 418-425.
96. Oberkofler CE, Dutkowski P, Stocker R, Schuepbach RA, Stover JF, Clavien PA, Béchir M,. Model of end stage liver disease (MELD) score greater than 23 predicts length of stay in the ICU but not mortality in liver transplant recipients. Crit Care 2010; 14: R117.
97. Bellomo R, Ronco C, Kellum JA, Mehta RL, Palevsky P,. Acute renal failure-definition, outcome measures, animal models, fluid therapy and information technology needs: the Second International Consensus Conference of the Acute Dialysis Quality Initiative (ADQI) Group. Crit Care 2004; 8: R204-R212.
98. Martin PY, Gines P, Schrier RW,. Nitric oxide as a mediator of hemodynamic abnormalities and sodium and water retention in cirrhosis. N Engl J Med 1998; 339: 533-541. (Pubitemid 28384887)
99. Arroyo V, Gines P, Gerbes AL, Dudley FJ, Gentilini P, Laffi G, et al. Definition and diagnostic criteria of refractory ascites and hepatorenal syndrome in cirrhosis. International Ascites Club. Hepatology 1996; 23: 164-176. (Pubitemid 26012105)
100. Skagen C, Einstein M, Lucey MR, Said A,. Combination treatment with octreotide, midodrine, and albumin improves survival in patients with type 1 and type 2 hepatorenal syndrome. J Clin Gastroenterol 2009; 43: 680-685.
101. Moreau R, Lebrec D,. The use of vasoconstrictors in patients with cirrhosis: type 1 HRS and beyond. Hepatology 2006; 43: 385-394.
102. Wong F, Pantea L, Sniderman K,. Midodrine, octreotide, albumin, and TIPS in selected patients with cirrhosis and type 1 hepatorenal syndrome. Hepatology 2004; 40: 55-64. (Pubitemid 38868923)
103. Stravitz RT, Kramer AH, Davern T, Shaikh AO, Caldwell SH, Mehta RL, et al. Acute Liver Failure Study Group. Intensive care of patients with acute liver failure: recommendations of the U.S. Acute Liver Failure Study Group. Crit Care Med 2007; 35: 2498-2508. (Pubitemid 351339009)
104. Davenport A, Will EJ, Davison AM,. Effect of renal replacement therapy on patients with combined acute renal and fulminant hepatic failure. Kidney Int 1993; 41: S245-S251.
105. Davenport A, Will EJ, Davidson AM,. Improved cardiovascular stability during continuous modes of renal replacement therapy in critically ill patients with acute hepatic and renal failure. Crit Care Med 1993; 21: 328-338. (Pubitemid 23097026)
106. Davenport A,. Is there a role for continuous renal replacement therapies in patients with liver and renal failure. Kidney Int 1999; 56: S62-S66.
107. Meier-Kriesche HU, Gitomer J, Finkel K, DuBose T,. Increased total to ionized calcium ratio during continuous venovenous hemodialysis with regional citrate anticoagulation. Crit Care Med 2001; 29: 748-752. (Pubitemid 32299711)
108. Larner AJ, Vickers CR, Adu D, Buckels JA, Elias E, Neuberger J,. Correction of severe hyponatraemia by continuous arteriovenous haemofiltration before liver transplantation. BMJ 1988; 297: 1514-1515. (Pubitemid 19007554)
109. Ruiz R, Kunitake H, Wilkinson AH, Danovitch GM, Farmer DG, Ghobrial RM, et al. Long-term analysis of combined liver and kidney transplantation at a single center. Arch Surg 2006; 141: 735-741. (Pubitemid 44268509)
110. Charlton MR, Wall WJ, Ojo AO, Gines P, Textor S, Shihab FS, et al.; International Liver Transplantation Society Expert Panel. Report of the first international liver transplantation society expert panel consensus conference on renal insufficiency in liver transplantation. Liver Transpl 2009; 15: S1-S34.
111. Davis CL, Feng S, Sung R, Wong F, Goodrich NP, Melton LB, et al. Simultaneous liver-kidney transplantation: evaluation to decision making. Am J Transplant 2007; 7: 1702-1709. (Pubitemid 46905445)
112. Wadei HM, Geiger XJ, Cortese C, Mai ML, Kramer DJ, Rosser BG, et al. Kidney allocation to liver transplant candidates with renal failure of undetermined etiology: role of percutaneous renal biopsy. Am J Transplant 2008; 8: 2618-2626.
113. Ruiz R, Barri YM, Jennings LW, Chinnakotla S, Goldstein RM, Levy MF, et al. Hepatorenal syndrome: a proposal for kidney after liver transplantation (KALT). Liver Transpl 2007; 13: 838-843. (Pubitemid 46947848)
114. Simpson N, Cho YW, Cicciarelli JC, Selby RR, Fong TL,. Comparison of renal allograft outcomes in combined liver-kidney transplantation versus subsequent kidney transplantation in liver transplant recipients: analysis of UNOS Database. Transplantation 2006; 82: 1298-1303. (Pubitemid 44832912)
115. Millard CE,. The NIH Consensus Development Conference on liver transplantation. R I Med J 1984; 67: 69-71.
116. Gibbons RD, Meltzer D, Duan N,. Waiting for organ transplantation. Institute of Medicine Committee on Organ Transplantation. Science 2000; 287: 237-238.
117. Freeman RB Jr, Wiesner RH, Harper A, McDiarmid SV, Lake J, Edwards E, et al.; UNOS/OPTN Liver Disease Severity Score, UNOS/OPTN Liver and Intestine, and UNOS/OPTN Pediatric Transplantation Committees. The new liver allocation system: moving toward evidence-based transplantation policy. Liver Transpl 2002; 8: 851-858. (Pubitemid 35012300)
118. Schaubel DE, Guidinger MK, Biggins SW, Kalbfleisch JD, Pomfret EA, Sharma P, Merion RM,. Survival benefit-based deceased-donor liver allocation. Am J Transplant 2009; 9: 970-981.
119. Brown RS Jr, Kumar KS, Russo MW, Kinkhabwala M, Rudow DL, Harren P, et al. Model for end-stage liver disease and Child-Turcotte-Pugh score as predictors of pretransplantation disease severity, posttransplantation outcome, and resource utilization in United Network for Organ Sharing status 2A patients. Liver Transpl 2002; 8: 278-284. (Pubitemid 34257211)
120. Barr ML, Belghiti J, Villamil FG, Pomfret EA, Sutherland DS, Gruessner RW, et al. A report of the Vancouver Forum on the care of the live organ donor: lung, liver, pancreas, and intestine data and medical guidelines. Transplantation 2006; 81: 1373-1385. (Pubitemid 43847145)
121. Volk ML, Hernandez JC, Lok AS, Marrero JA,. Modified Charlson comorbidity index for predicting survival after liver transplantation. Liver Transpl 2007; 13: 1515-1520. (Pubitemid 350168191)
122. Krowka MJ, Plevak DJ, Findlay JY, Rosen CB, Wiesner RH, Krom RA,. Pulmonary hemodynamics and perioperative cardiopulmonary-related mortality in patients with portopulmonary hypertension undergoing liver transplantation. Liver Transpl 2000; 6: 443-450. (Pubitemid 30489117)
123. Harinstein ME, Flaherty JD, Ansari AH, Robin J, Davidson CJ, Rossi JS, et al. Predictive value of dobutamine stress echocardiography for coronary artery disease detection in liver transplant candidates. Am J Transplant 2008; 8: 1523-1528. (Pubitemid 351989500)
124. Vaquero J, Fontana RJ, Larson AM, Bass NM, Davern TJ, Shakil AO, et al. Complications and use of intracranial pressure monitoring in patients with acute liver failure and severe encephalopathy. Liver Transpl 2005; 11: 1581-1589. (Pubitemid 43072637)
125. Halazun KJ, Hardy MA, Rana AA, Woodland DC 4th, Luyten EJ, Mahadev S, et al. Negative impact of neutrophil-lymphocyte ratio on outcome after liver transplantation for hepatocellular carcinoma. Ann Surg 2009; 250: 141-151.
126. Kulik L, Abecassis M,. Living donor liver transplantation for hepatocellular carcinoma. Gastroenterology 2004; 127: S277-S282. (Pubitemid 39423397)
127. Bert F, Larroque B, Paugam-Burtz C, Janny S, Durand F, Dondero F, et al. Microbial epidemiology and outcome of bloodstream infections in liver transplant recipients: an analysis of 259 episodes. Liver Transpl 2010; 16: 393-401.
128. Shi SH, Kong HS, Xu J, Zhang WJ, Jia CK, Wang WL, et al. Multidrug resistant gram-negative bacilli as predominant bacteremic pathogens in liver transplant recipients. Transpl Infect Dis 2009; 11: 405-412.
129. Steinman TI, Becker BN, Frost AE, Olthoff KM, Smart FW, Suki WN, Wilkinson AH,. Guidelines for the referral and management of patients eligible for solid organ transplantation. Transplantation 2001; 71: 1189-1204. (Pubitemid 32507132)
130. McCashland T, Watt K, Lyden E, Adams L, Charlton M, Smith AD, McGuire BM, Biggins SW BM, Neff G, Burton JR Jr, Vargas H, Donovan J, Trotter J, Faust T,. Retransplantation for hepatitis C: results of a U.S. multicenter retransplant study. Liver Transpl 2007; 13: 1246-1253. (Pubitemid 47457051)
131. Locke JE, Warren DS, Singer AL, Segev DL, Simpkins CE, Maley WR, Montgomery RA, Danovitch G, Cameron AM,. Declining outcomes in simultaneous liver-kidney transplantation in the MELD era: ineffective usage of renal allografts. Transplantation 2008; 85: 935-942. (Pubitemid 351543154)